Developing novel therapeutics for cardiovascular diseases.

About

CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval.  CinCor’s focus is on cardiovascular, metabolic and kidney diseases.  CinCor’s lead program is CIN-107, a novel aldosterone synthase inhibitor.

CIN-107

CIN-107 works through the renin-angiotensin-aldosterone system (RAAS), which is a responsible for regulating the body’s fluid and electrolyte balance. CIN-107 is a highly selective aldosterone synthase inhibitor being developed for large unmet medical needs, including resistant hypertension and primary aldosteronism.  Hypertension guidelines were changed in 2017 by the Joint National Committee (JNC) based on overwhelming data demonstrating that reducing blood pressures to less than 130/80 mmHg reduced the risk of cardiac events, particularly heart attacks and stroke.  With this target blood pressure, approximately 17% of the hypertensive population do not achieve goal levels despite the use of combinations of blood pressure lowering medications, and are considered treatment resistant.  Data have shown the risk of MI, stroke, and death in adults with resistant hypertension to be 2- to 6-fold higher than in hypertensive adults who achieve goal levels.

Contact Us

CinCor Pharma

5375 Medpace Way

Cincinnati, OH 45227

info@cincor.com


Copyright CinCor Pharma, Inc. 2019 – All rights reserved